Sydney, July 21, 2006 (ABN Newswire) - Starpharma Holdings Limited (ASX: SPL) - VivaGel IND for Genital Herpes Trial clears US FDA - Dr Jackie Fairley, CEO; Boardroomradio is pleased to announce that Starpharma Holdings Limited (ASX: SPL) has published an audio file. The following presentation "VivaGel IND for Genital Herpes Trial clears US FDA" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Computers set up for access to the Internet, including at least a 28.8k modem and sufficient memory and hard disk space to run Windows Media Player or Real Player, should be able to run BRR media files.
About STARPHARMA HOLDINGS LIMITED
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
About Boardroomradio
Sydney-based Boardroomradio (BRR) is an Investor Relations multi-media portal delivering audio webcasts to the investment community, including brokers, fund managers, analysts, and private investors.
News 
